Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 24, 2021

SELL
$3.1 - $4.32 $3,100 - $4,320
-1,000 Reduced 43.48%
1,300 $5,000
Q2 2021

Jul 30, 2021

SELL
$4.45 - $9.91 $30,718 - $68,408
-6,903 Reduced 75.01%
2,300 $10,000
Q1 2021

Apr 29, 2021

BUY
$7.76 - $10.43 $71,415 - $95,987
9,203 New
9,203 $84,000
Q2 2020

Jul 10, 2020

SELL
$2.6 - $7.32 $7,150 - $20,130
-2,750 Closed
0 $0
Q4 2019

Jan 22, 2020

BUY
$1.8 - $5.04 $1,350 - $3,780
750 Added 37.5%
2,750 $13,000
Q2 2019

Aug 07, 2019

SELL
$2.7 - $4.96 $2,700 - $4,960
-1,000 Reduced 33.33%
2,000 $10,000
Q1 2019

Apr 29, 2019

BUY
$3.1 - $4.54 $9,300 - $13,620
3,000 New
3,000 $14,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Patriot Financial Group Insurance Agency, LLC Portfolio

Follow Patriot Financial Group Insurance Agency, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Patriot Financial Group Insurance Agency, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Patriot Financial Group Insurance Agency, LLC with notifications on news.